最新消息分類研發臨床進展

漢康生技於2026 ESMO靶向抗癌治療亞洲大會發表兩場口頭報告，展現下一代免疫療法臨床進展 HanchorBio Presents Two Oral Presentations at ESMO TAT Asia 2026 Highlighting Progress Across Its Next-Generation Immunotherapy Pipeline

HanchorBio announced that two company-sponsored clinical programs were featured in oral presentations at the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress 2026, ESMO TAT Asia 2026, held in Hong Kong.

6 月 13, 2026

漢康生技於 FOCIS 2026 發表突破性數據，支持先天免疫產品引擎布局腫瘤與自體免疫疾病 HanchorBio Presents Late-Breaking Data at FOCIS 2026 Supporting Innate-Immune Product Engine Across Oncology and Autoimmune Disease

HanchorBio announced the presentation of late-breaking clinical and translational data at the Federation of Clinical Immunology Societies Annual Meeting, FOCIS 2026, being held June 9-12, 2026, in San Francisco.

6 月 10, 2026

漢康生技於 ASCO 2026 發表兩項摘要，展現 HCB101 聯合療法臨床活性與 HCB301 首次人體試驗進展 HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress

HanchorBio announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

6 月 01, 2026

漢康生技宣布 HCB101聯合治療研究之結直腸癌臨床研究觀察到首例部分緩解（PR）HanchorBio Announces First Confirmed Partial Response in Colorectal Cancer Cohort of Ongoing HCB101-201 Combination Study

HanchorBio announced the first confirmed partial response (PR) in the colorectal cancer (CRC) cohort of its ongoing clinical study evaluating HCB101 in combination with standard-of-care regimens.

5 月 18, 2026

漢康生技HCB206拓展自體免疫疾病應用，加速推進臨床前關鍵試驗 HanchorBio Expands HCB206 Development into Autoimmune Diseases and Advances IND-Enabling Studies

HanchorBio announced that its internally developed dual-target fusion protein candidate, HCB206, has demonstrated therapeutic potential in preclinical studies across both oncology and autoimmune disease models.

5 月 11, 2026

漢康生技與河北清華發展研究院展開 HCB101 作用機制研究合作 HanchorBio Launches HCB101 Mechanism Collaboration Study with Tsinghua University

HanchorBio started a research collaboration with the Institute of Tsinghua University, Hebei, to further characterize the antitumor mechanisms and translational biology of HCB101, the Company’s AI-guided, structurally engineered, Fc-based fusion protein targeting the CD47-SIRPα axis.

5 月 05, 2026

漢康生技於台灣癌症聯合年會 (TJCC) 展現次世代合併治療骨幹潛力、腫瘤以外平台拓展與三特異性機制進展 HanchorBio Highlights Next Generation Combination Backbone Potential, Platform Expansion Beyond Oncology, and Tri-specific Mechanistic Progress at TJCC 2026

HanchorBiopresented at the 30th Taiwan Joint Cancer Conference (TJCC 2026). Across a keynote lecture and the company symposium, HanchorBio highlighted clinical and translational data supporting HCB101 as a clinically versatile innate immune backbone and presented a working mechanism framework for its next-generation tri-specific program, HCB301.

5 月 04, 2026

漢康生技與陽明交大啟動AI賦能藥物研發合作　推進次世代創新生物藥開發 HanchorBio and NYCU Launch AI-Enabled Drug Discovery Collaboration to Advance Next-Generation Biologics

HanchorBio started a research collaboration with the College of Engineering Bioscience at National Yang Ming Chiao Tung University (NYCU) to advance AI-enabled biologics discovery.

4 月 29, 2026

漢康生技發布 HCB101 頭頸癌數據：單藥展現持久活性，低劑量聯合 PD-1 觀察到完全緩解 HanchorBio Reports Head and Neck Cancer Data for HCB101, Including Durable Monotherapy Activity and Complete Response at Low Dose in Combination with PD-1

HanchorBio reported updated clinical observations in head and neck squamous cell carcinoma (HNSCC) across both monotherapy and combination settings for HCB101, its rationally engineered SIRPα-Fc fusion protein functioning as an innate immune checkpoint blockade.

4 月 22, 2026

漢康生技報告2026年上半年科學溝通成果，並預告第二季將參與多項學術會議HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation

HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.

4 月 20, 2026